Kalaris Therapeutics Inc
NASDAQ Global MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Kalaris Therapeutics Inc. functions as a clinical-stage biopharmaceutical firm. The company is dedicated to advancing and commercializing innovative treatments for widespread retinal conditions. Its primary focus is on TH103, a distinguished anti-vascular endothelial growth factor (VEGF) investigational therapy. Engineered for enhanced VEGF inhibition and extended retention within the retina, TH103 acts as a fully humanized recombinant fusion protein, functioning as a decoy receptor. This therapy is currently being assessed in Phase 1 clinical trials for neovascular age-related macular degeneration (nAMD), with plans to expand its application to other neovascular and exudative retinal diseases, including diabetic macular edema (DME) and retinal vein occlusion (RVO). Kalaris recently completed a merger, securing substantial funding to support its ongoing clinical development efforts. The objective is to mitigate the limitations of existing therapies, aiming to lessen the treatment burden on patients.
Kalaris Expands Leadership Team Appointing Liisa Bayko as Chief Financial Officer
Kalaris Therapeutics Reports Positive TH103 Phase 1a SAD Results from Expanded Neovascular AMD Cohorts
Kalaris Appoints Laurie Keating to Board of Directors
Kalaris Announces Upcoming Presentation of TH103 Phase 1a Clinical Data at American Society of Retina Specialists; Ph 1b/2 Clinical Trial Actively Enrolling
Kalaris to Present at Clinical Trials at the Summit 2026
Kalaris Reports First Quarter 2026 Financial Results and Provides Business Updates
Kalaris Reports Full Year 2025 Financial Results and Provides Business Updates
Kalaris Therapeutics (NASDAQ:KLRS) Director Srinivas Akkaraju Buys 479,847 Shares of Stock
Kalaris Therapeutics: Phase 1a Data De-Risks The Path To 2026 Catalysts
Kalaris Therapeutics: TH103 Trial Success And $50M Raise Set Stage For Growth
Kalaris Therapeutics Announces Oversubscribed $50.0 Million Private Placement
Kalaris Therapeutics Reports Positive Initial Phase 1a Data for TH103 in Treatment-Naïve Neovascular AMD
Kalaris to Present at Noble Capital Markets 21st Annual Emerging Growth Equity Conference
Kalaris Reports Third Quarter 2025 Financial Results and Provides Business Updates
Kalaris Expands Leadership Team Appointing Matthew Gall, MBA, as Chief Financial Officer
Kalaris to Present at Stifel 2025 Annual Healthcare Conference
UPDATE – Kalaris Therapeutics Now Enrolling Phase 1b/2 Multiple Ascending Dose Study of TH103 in Neovascular Age-Related Macular Degeneration
Kalaris Therapeutics Inc. (KLRS) Upgraded to Buy: Here's What You Should Know
Kalaris Reports Second Quarter 2025 Financial Results and Provides Business Updates
Bernstein Liebhard LLP Announces Proposed Class Action Settlement on Behalf of Purchasers of AlloVir, Inc. Securities